– VIEW OUR SHORTLIST CANDIDATES –
On 23 March, the Swiss Medtech Award jury met under the leadership of jury president Prof Mirko Meboldt to review the 55 Swiss Medtech Award applications submitted. In addition to the main criteria of patient benefit generated, new solutions for healthcare, groundbreaking technologies and «Swissness», the dossiers were examined and evaluated on 10 further criteria.
6 candidates made it to the shortlist and were invited to the jury hearing on 27 April 2021, where they will face the questions of the jury. At the end of the day, the jury will select the three finalists, who will be presented at the Swiss Medtech Day on 8 September 2021.
Who can apply?
Participation in the Swiss Medtech Award is open to companies, research institutions or syndicates from the Swiss medical technology industry.
The following criteria must be met in order to be admitted to the competition. In cases where it is unclear whether a candidate fulfils the criteria, the jury has final say.
Project-related criteria
At least one of the following project-related criteria must be met.
- Patient benefit generated
The candidates develop new medical products and can demonstrate a benefit to patients – in studies or on the market. - New health care solutions
The candidates have implemented new solutions that lead to identifiable cost savings in the healthcare sector. - Pioneering advancements
The candidates have contributed to the development of groundbreaking technologies or procedures that will strengthen the Swiss medical industry.
Formal criteria
Both of the formal criteria below must be met.
- «Swissness» factor
The achievements and provision of services must have been performed to a significant extent within Switzerland. - Record of achievement
Candidates can provide supporting documents and/or references as evidence of their achievements.
In addition, applicants must read and accept our Terms of Participation.
Important dates
The following dates mark the milestones of the evaluation process. Applicants are asked to save the dates.
27 April 2021
Jury hearing and nomination of finalists
The shortlisted candidates each present their project to the jury. At the end of the day, the jury will nominate the three finalists.
8 September 2021
Award ceremony at Swiss Medtech Day
The finalists will get the chance to present their innovation live on stage during Swiss Medtech Day, Switzerland’s most important medical technology conference. The winner will be announced during the award ceremony at the end of the conference.
Jury
Prof Dr Mirko Meboldt
President of the Jury
Chair of Product Development
& Engineering
ETH Zurich
Prof Dr med Edouard Battegay
Member of the Jury
Head Innovation Hub, ICMC,
University Zurich
Owner IntelliXess AG
Hans Ulrich Lehmann
Member of the Jury
Senior Vice President Technology
Ypsomed
Sabina Sperisen
Member of the Jury
CEO
Lichtsteiner Foundation
Stephan Oehler
Member of the Jury
Head of Technology & Testing
Straumann
Donors
The Lichtsteiner Foundation helps pioneers bring their inventions to life by investing in early stage start-ups in the fields of medical technology, life science, mental health, public health and wellbeing. The foundation focuses on impact investing by providing funding in the form of equity.
The Straumann Group is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Dental Wings, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, biomaterials and digital solutions for use in tooth replacement and restoration or to prevent tooth loss.
Headquartered in Basel, Switzerland, the Group currently employs more than 7700 people worldwide and its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.
With over 30 years’ experience, the Ypsomed Group is a renowned diabetes specialist and principle developer and manufacturer of injection and infusion systems for self-medication. As a leader in innovation and technology, Ypsomed is the preferred partner of pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems which administer liquid drugs. Ypsomed promotes its product portfolio under the following umbrella brands: mylife Diabetescare sells directly to patients or via pharmacies and clinics, and YDS Ypsomed Delivery Systems deals business-to-business with pharmaceutical companies.